Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells
Specific cancer cell vulnerabilities can provide an opportunity for the development of novel cancer therapeutics. In this study the authors demonstrate that targeting ADAR1 represents a potential therapeutic vulnerability in cancers with activated interferon response signatures.
Guardado en:
Autores principales: | Hugh S. Gannon, Tao Zou, Michael K. Kiessling, Galen F. Gao, Diana Cai, Peter S. Choi, Alexandru P. Ivan, Ilana Buchumenski, Ashton C. Berger, Jonathan T. Goldstein, Andrew D. Cherniack, Francisca Vazquez, Aviad Tsherniak, Erez Y. Levanon, William C. Hahn, Matthew Meyerson |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/101c1efd608349f2b4bd50157c1c3989 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Adenosine deaminase modulates metabolic remodeling and orchestrates joint destruction in rheumatoid arthritis
por: Sai Krishna Srimadh Bhagavatham, et al.
Publicado: (2021) -
A Case of Deficiency of Adenosine Deaminase 2: 28 years of Diagnostic Challenges
por: Clara Pardinhas, et al.
Publicado: (2021) -
Novel Adenosine Deaminase 2 (ADA2) Mutations Associated With Hematological Manifestations
por: Reem Albalawi MSc, et al.
Publicado: (2021) -
Optimising the utility of pleural fluid adenosine deaminase for the diagnosis of tuberculous pleural effusion
por: Nai-Chien Huan, et al.
Publicado: (2021) -
Adenosine deaminase-1 delineates human follicular helper T cell function and is altered with HIV
por: Virginie Tardif, et al.
Publicado: (2019)